论文部分内容阅读
目的观察单唾液酸四己糖神经节苷脂(博司捷)联合依达拉奉治疗脑出血保守治疗患者的临床疗效。方法 100例脑出血保守治疗患者,按照随机数字表法分为观察组和对照组,各50例。对照组在常规治疗的基础上加用神经保护剂博司捷;观察组在对照组的基础上加用依达拉奉;两组的疗程均为14 d。观察两组治疗前后神经功能缺损评分(NIHSS评分)、日常生活活动能力指数(Barthel指数)和血清超敏C反应蛋白(hs-CRP)水平的变化,评价临床疗效。结果治疗前两组的NIHSS评分、Barthel指数及血清hs-CRP水平差异无统计学意义(P>0.05);治疗后,两组的NIHSS评分、Barthel指数及血清hs-CRP水平均较治疗前明显改善,观察组改善情况明显优于对照组,差异具有统计学意义(P<0.05);观察组和对照组的临床总有效率分别为90%、72%,观察组明显优于对照组,差异具有统计学意义(P<0.05)。结论博司捷联合依达拉奉能明显减轻脑出血保守治疗患者炎性反应,改善神经功能和日常生活活动能力,疗效显著,值得临床推广应用。
Objective To observe the clinical efficacy of monosialotetrahexosyl ganglioside (Bosch Jie) combined with edaravone in patients with conservative treatment of cerebral hemorrhage. Methods 100 patients with conservative treatment of cerebral hemorrhage were divided into observation group and control group according to the random number table method, 50 cases each. The control group was treated with the neuroprotective agent, Bostik, on the basis of routine treatment. The observation group was given edaravone on the basis of the control group. Both groups took 14 days. The changes of NIHSS score, Barthel index and hs-CRP level before and after treatment were observed to evaluate the clinical curative effect. Results There was no significant difference in NIHSS score, Barthel index and serum hs-CRP level between the two groups before treatment (P> 0.05). After treatment, NIHSS score, Barthel index and serum hs-CRP level in both groups were significantly higher than those before treatment (P <0.05). The total clinical effective rates in the observation group and the control group were 90% and 72%, respectively, and the observation group was significantly better than the control group, the difference was statistically significant Statistically significant (P <0.05). Conclusion The combination of bosnir and edaravone can significantly reduce the inflammatory response in patients with conservative treatment of cerebral hemorrhage, improve neurological function and activities of daily living, with significant curative effect and worthy of clinical application.